Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 051.8 INR -0.91% Market Closed
Market Cap: 937.2B INR

Lupin Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lupin Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Lupin Ltd
NSE:LUPIN
Operating Income
₹51.6B
CAGR 3-Years
168%
CAGR 5-Years
35%
CAGR 10-Years
7%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Operating Income
₹67.3B
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Operating Income
₹60.6B
CAGR 3-Years
22%
CAGR 5-Years
20%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Operating Income
₹130.6B
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
9%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Operating Income
₹60B
CAGR 3-Years
34%
CAGR 5-Years
20%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Operating Income
₹31.9B
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
6%
No Stocks Found

Lupin Ltd
Glance View

In the bustling landscape of the global pharmaceutical industry, Lupin Ltd. stands as a testament to the transformative power of innovation and strategic foresight. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin embarked on its journey with a clear vision: to deliver high-quality drugs at affordable prices. Over the years, it has adeptly navigated the complex world of pharmaceuticals to become a formidable player in the generics market. Its success is built on a robust portfolio that includes a diverse range of generic and branded formulations across many therapeutic segments such as cardiovascular, diabetology, asthma management, and anti-tuberculosis. The company prioritizes intensive research and development, paving the way for both the introduction of new generics and the development of advanced drug delivery systems. Such focus ensures Lupin maintains a competitive edge in both established markets like the United States and emerging markets across Asia and Africa. The company’s financial engine is powered largely by its extensive manufacturing and distribution capabilities, which are strategically positioned across the globe to maximize efficiency and meet demand. With state-of-the-art facilities in India supplemented by strategic acquisitions and partnerships overseas, Lupin produces a wide array of active pharmaceutical ingredients (APIs) and finished dosages, allowing it to capture value across different stages of the drug supply chain. This vertically integrated model not only enhances profit margins but also provides the agility to respond quickly to market shifts. Furthermore, Lupin's strategic emphasis on biosimilars and specialty drugs reinforces its commitment to innovation, unlocking new revenue streams amid growing global healthcare demands. As Lupin continues to expand its footprint, it remains anchored in its mission to improve healthcare outcomes, embodying a legacy where profitability harmoniously aligns with purpose.

LUPIN Intrinsic Value
1 821.54 INR
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Lupin Ltd's Operating Income?
Operating Income
51.6B INR

Based on the financial report for Sep 30, 2025, Lupin Ltd's Operating Income amounts to 51.6B INR.

What is Lupin Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
7%

Over the last year, the Operating Income growth was 52%. The average annual Operating Income growth rates for Lupin Ltd have been 168% over the past three years , 35% over the past five years , and 7% over the past ten years .

Back to Top